Supporting Information for

## Hybrid Biosynthesis of Roseobacticides from Algal and Bacterial Precursor Molecules

Mohammad R. Seyedsayamdost,<sup>†,\*</sup> Rurun Wang,<sup>†</sup> Roberto Kolter,<sup>‡</sup> and Jon Clardy<sup>§,\*</sup>

<sup>†</sup>Department of Chemistry, Princeton University, Princeton, NJ 08544 <sup>‡</sup>Department of Microbiology & Immunology and Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02115

\*email: mrseyed@princeton.edu; jon\_clardy@hms.harvard.edu

Reagents and general procedures. Yeast extract and tryptone were purchased from Becton Dickinson, Ring-<sup>2</sup>H<sub>4</sub>-L-tyrosine, ring-<sup>2</sup>H<sub>5</sub>-L-phenylalanine, ring-<sup>2</sup>H<sub>5</sub>-L-tryptophan, 2-<sup>13</sup>C-malonic acid, and ring-<sup>2</sup>H<sub>4</sub>-4-hydroxybenzaldehyde were purchased from Cambridge Isotopes Laboratories. All other reagents, including sea salt, *p*-coumaric acid, sinapic acid, phenylacetic acid, 1,2-<sup>13</sup>C-phenylacetic acid, ring-<sup>2</sup>H<sub>5</sub>-phenylacetic acid, 3-fluoro-DL-tyrosine, ring-<sup>2</sup>H<sub>5</sub>phenylglycine, ring-<sup>2</sup>H<sub>5</sub>-indoleacetic acid, unlabeled L-phenylalanine, NAD, and phenylalanine dehydrogenase, the latter three required for the enzymatic synthesis of isotopically labeled phenylpyruvic acid, were obtained from Sigma-Aldrich. <sup>34</sup>S-L-Cysteine was a kind gift of Prof. Jeroen Dickschat.<sup>1</sup> UV-visible absorbance spectra were collected an Agilent Cary 60 Spectrophotometer. HPLC purifications were carried out on an Agilent 1200 Series analytical HPLC system equipped with a photo diode array detector and an automated fraction collector, or on an Agilent 1200 Series preparative HPLC system also equipped with the same modules. Low resolution HPLC-MS analysis was performed on an Agilent 1200 Series HPLC system equipped with a diode array detector and a 6130 Series ESI mass spectrometer using an analytical Phenomenex Luna C18 column (5  $\mu$ m, 4.6 × 100 mm) operating at 0.7 mL/min with a gradient of 10 % MeCN in H<sub>2</sub>O (+0.1% formic acid) to 100% MeCN (+0.1% formic acid) over 25 min. High resolution HPLC-ESI-MS (HR-MS) and tandem MS (MS/MS) were out on a 6540 UHD Accurate Mass Q-tof LC-MS system (Agilent), which consists of a 1260 Infinity Series HPLC system, an automated liquid sampler, a diode array detector, a JetStream ESI source, and the 6540 Series Q-tof. The HR-HPLC-MS was calibrated to within 1 ppm. Samples were resolved on a Poroshell 120 EC-C18 column (Agilent, 2.7 µm, 3 x 50 mm) operating at 0.4 mL/min with a gradient of 10% MeCN in H<sub>2</sub>O to 95% MeCN in H<sub>2</sub>O over 13 min. Both MeCN and H<sub>2</sub>O contained 0.1% (v/v) formic acid. <sup>1</sup>H and 2D NMR spectra were recorded in the inversedetection probe of a Varian Inova spectrometer (600 MHz for <sup>1</sup>H, 150 MHz for <sup>13</sup>C) at the Harvard Medical School NMR Facility. <sup>13</sup>C NMR spectra were recorded on the same instrument with a broad-band probe. NMR spectra of fluoro-roseobactcide A were recorded at the Princeton Chemistry NMR Facility on a Bruker Avance III 800 MHz spectrometer equipped with a cryoprobe for <sup>1</sup>H and <sup>19</sup>F measurements, and a Bruker Avance III 500 MHz instrument equipped with a <sup>1</sup>H-optimized cryoprobe for gCOSY experiments. Spectra were routinely obtained in MeOH- $d_4$ , unless otherwise indicated, and the chemical shifts were referenced to the residual solvent peak(s).

**Synthesis of isotopically-labeled precursors.** Isotopically-labeled *p*-coumaric acid,<sup>2</sup> phenyl-pyruvic acid,<sup>3</sup> and phenylglyoxylic acid<sup>4</sup> were synthesized as previously described with minor modifications.

 $2^{-13}C$ -p-coumaric acid and ring- ${}^{2}H_{4}$ -p-coumaric acid. To a 50 mL pear-shaped flask fitted with a stir bar were added 4.5 mL of acetic acid, 9 mmol of 4-hydroxybenzaldehye (1.1 g), and 9 mmol of morpholine (0.8 g). The mixture was stirred for 10 minutes before supplementing with 9 mmol of malonic acid (0.93 g). The reaction was refluxed for 1.5 h at 105°C, then cooled by stirring in ice-cold water for 15 min. To precipitate the product, the mixture was poured into 12 mL of ice-cold water, incubated on ice for 30 min, and then filtered. The residue was washed twice with a small amount of water and dried on the filter providing pure p-coumaric acid with a yield of 54%. 2-13C-malonic acid or ring-2H4-hydroxybenzaldehyde was used to generate the desired isotopically-labeled p-coumaric acids, which were characterized by HPLC-MS using authentic standards, NMR, and HR-MS, as described above. Authentic pCA: HPLC-MS  $R_t = 8.0$ min,  $\lambda_{max} = 310$  nm, LR-ESI-MS  $[M+H]^+_{expt} = 165.1$ ,  $[M+H]^+_{calc} = 165.1$ . 2-<sup>13</sup>C-pCA: HPLC-MS  $R_t = 8.0 \text{ min}, \lambda_{max} = 310 \text{ nm}, \text{LR-ESI-MS} [M+H]^+_{expt} = 166.1, [M+H]^+_{calc} = 166.1; \text{HR-MS}$  $[M+H]^{+}_{expt} = 166.0577, [M+H]^{+}_{calc} = 166.0585.$  Ring-<sup>2</sup>H<sub>4</sub>-pCA: HPLC-MS R<sub>t</sub> = 7.9 min,  $\lambda_{max} =$ 310 nm, LR-ESI-MS  $[M+H]^+_{expt} = 169.1$ ;  $[M+H]^+_{calc} = 169.1$ , HR-MS  $[M+H]^+_{expt} = 169.0795$ ,  $[M+H]^{+}_{calc} = 169.0803; {}^{1}H NMR (600 MHz, acetone-d_{6}) \delta = 6.37 (d, 1H, C2-{}^{1}H, 15.9 Hz), \delta =$ 7.65 (d, 1H, C3-<sup>1</sup>H, 15.9 Hz).

*Ring-*<sup>2</sup>*H<sub>5</sub>-phenylpyruvic acid.* To a 50 mL polypropylene Falcon tube equipped with a stir bar were added 10 mL of glycine buffer (0.1 M glycine, pH 10.8), 165 µmol of ring-<sup>2</sup>H<sub>5</sub>-Lphenylalanine, 95 µmol of cofactor NAD and 12 U of phenylalanine dehydrogenase (~2 mg). The reaction was stirred overnight at room temperature and reaction progress monitored by TLC using a solvent system of MeCN/H<sub>2</sub>O (4:1). After overnight incubation, the reaction was loaded onto a silica gel column (d=1.25 cm, l=18 cm), which had been equilibrated in EtOAc/MeOH/formic acid (98:1:1). The mixture was resolved isocratically and fractions containing ring-<sup>2</sup>H<sub>5</sub>-phenyl-pyruvic acid, as judged by HPLC-MS analysis, were pooled and concentrated in vacuo. The product was obtained in a 25% yield and was characterized by HPLC-MS using an authentic standard (phenylpyruvic acid) and by HR-MS. Authentic phenylpyruvic acid: HPLC-MS R<sub>t</sub> = 11.9 min,  $\lambda_{max}$  = 289 nm, LR-ESI-MS [M–H]<sup>-</sup><sub>expt</sub> = 163.0, [M–H]<sup>-</sup><sub>calc</sub> = 163.0. Ring-<sup>2</sup>H<sub>5</sub>-phenylpyruvic acid: HPLC-MS R<sub>t</sub> = 11.9 min,  $\lambda_{max}$  = 290 nm, LR- ESI-MS  $[M-H]_{expt}^{-} = 168.0$ ,  $[M-H]_{calc}^{-} = 168.0$ ; HR-MS  $[M-H]_{expt}^{-} = 168.0726$ ,  $[M-H]_{calc}^{-} = 168.0709$ .


 $1,2^{-13}C_2$ -phenylglycoxylic acid and ring-<sup>2</sup>H<sub>5</sub>-phenylglyoxylic acid. To a 50 mL pear-shaped flask fitted with a stir bar were added 8 mL of xylenes, 1.45 mmol of isotopically-labeled phenylacetic acid, and 1.6 mmol of SeO<sub>2</sub>. The reaction was refluxed for 5 h at 155°C, cooled, and filtered to remove excess SeO<sub>2</sub>. The solvent was azeotroped with water (2:3 water/xylenes by weight) and evaporated in vacuo. The resulting mixture was dissolved in a small volume of MeOH, supplemented with 1.5 g of silica gel and dry-loaded onto a silica gel column (20g, d=1.25 cm, l=30 cm) that had been equilibrated in CH<sub>2</sub>Cl<sub>2</sub>/MeOH/formic acid (95:5:0.5). The column was resolved isocratically in the same solvent, in which phenylacetic acid and phenylglyoxylic acid had R<sub>f</sub> values of 0.4 and 0.12, respectively. This procedure afforded the corresponding product in a modest 10-20% yield. Despite the low yields, the procedure provided sufficient amounts of material to carry out the isotope feeding experiments. The isotopicallylabeled precursors, 1,2-13C2-phneylacetic acid and ring-2H5-phenylacetic acid, were easily recovered during the work-up and purification in good yields. HPLC-MS analyses of the synthetic phenylglyoxylic acids and authentic, unlabeled phenylglyoxylic acid, as described above, confirmed the identity of the products. Authentic phenylglyoxylic acid: HPLC-MS  $R_t$  = 8.2 min,  $\lambda_{max} = 250$  nm, 290 nm shoulder, LR-ESI-MS  $[M-H]^-_{expt} = 149.0 [M-H]^-_{calc} = 149.0$ . 1,2-<sup>13</sup>C<sub>2</sub>-phenylacetic acid: HPLC-MS  $R_t = 8.1 \text{ min}$ ,  $\lambda_{max} = 250 \text{ nm}$ , 290 nm shoulder, LR-ESI-MS  $[M-H]^{-}_{expt} = 151.0$ ,  $[M-H]^{-}_{calc} = 151.0$ . Ring-<sup>2</sup>H<sub>5</sub>-phenylglyoxylic acid: HPLC-MS R<sub>t</sub> = 8.1 min,  $\lambda_{max} = 250$  nm, 290 nm shoulder, LR-ESI-MS  $[M-H]_{expt}^{-} = 154.0$ ,  $[M-H]_{calc}^{-} = 154.0$ ; HR-MS  $[M-H]_{expt}^{-} = 154.0559$ ,  $[M-H]_{calc}^{-} = 154.0553$ .

**Growth of** *P. inhibens* **DSM 17395 and purification of roseobacticides.** *P. inhibens* DSM 17395 was used throughout this study. This is the same strain used in our previous reports.<sup>5,6</sup> Formerly known as *Phaeobacter gallaeciensis* (BS107), it was recently renamed to *P. inhibens* DSM 17395.<sup>7</sup>


*P. inhibens* DSM 17395 was routinely cultured in half-strength YTSS media (referred to as YTSS throughout) consisting of the following (per L): 20 g Sigma sea salt, 2 g yeast extract, and 1.25 g tryptone. To initiate production cultures, wild-type *P. inhibens* DSM 17395 on a YTSS agar plate (YTSS containing 1.6% w/v agar) was used to inoculate a 5 mL YTSS overnight

culture in a 14 mL bacterial culture tube. After ~15 h at 30°C and 250 rpm, the culture was diluted 50-fold into a 500 mL Erlenmeyer flask containing 50 mL of YTSS media. Overnight growth of this culture at 30°C and 160 rpm provided the inoculum for large-scale cultures. The 50 mL overnight culture was diluted 50-fold into 4-6 x 4 L flasks containing 400 mL of YTSS medium, 1 mM sinapic acid or 1 mM pCA (in the case of L-Tyr isotopomers), and any of the following isotopically-labeled compounds: 0.4 mM ring-<sup>2</sup>H<sub>3</sub>-L-Phe, 0.5 mM ring-<sup>2</sup>H<sub>5</sub>-L-Trp, 0.4 mM ring-<sup>2</sup>H<sub>4</sub>-L-Tyr, 0.4 mM 2-<sup>13</sup>C-L-Tyr, 0.4 mM 3-fluoro-DL-tyrosine, 0.4 mM 1,2-<sup>13</sup>C-phenylacetic acid, or 0.4 mM ring-<sup>2</sup>H<sub>5</sub>-phenylacetic acid. When assessing incorporation of pCA into roseobacticides, 4-6 x 4 L Erlenmeyer flasks were used containing 400 mL YTSS and 1 mM ring-<sup>2</sup>H<sub>4</sub>-pCA or 1 mM 2-<sup>13</sup>C-pCA. The large-scale cultures were grown at 160 rpm and 30°C for 3 days. Roseobacticides were isolated as previously described in detail.<sup>5</sup>


The fate of labeled phenylpyruvic acid, phenylglyoxylic acid, phenylglycine, and Cys were assessed by HPLC-MS from small production cultures. In this case, the 50 mL culture in a 500 mL Erlenmeyer flask contained 1 mM sinapic acid and 0.4 mM of either ring-<sup>2</sup>H<sub>5</sub>-phenylpyruvic acid, 1,2-<sup>13</sup>C-phenyglyoxylic acid, ring-<sup>2</sup>H<sub>5</sub>-phenylglyoxylic acid, ring-<sup>2</sup>H<sub>5</sub>-phenylglycine, or <sup>34</sup>S-L-Cys. After 3 days, each culture was extracted once with an equal volume of EtOAc. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness in a speedvac. The dried residue was typically dissolved in 1 mL of MeOH, filtered, and 10-30 µL were subsequently analyzed on an Agilent low-resolution HPLC-ESI-MS and/or an Agilent Accurate Mass Q-tof HPLC-MS system, as described above.




**Figure S1**. HMBC spectrum of roseobacticide B isolated from production cultures of *P. inhibens* DSM 17395 containing 0.4 mM 1,2- $^{13}C_2$ -phenylacetic acid and 1 mM sinapic acid. The  $^{1}$ H,  $^{13}$ C, and HSQC spectra in Fig. 2 show that one  $^{13}$ C is incorporated at position 8. The HMBC spectrum above further corroborates this conclusion by demonstrating a strong correlation between H6 and C8. The structure and numbering of roseobacticide B with a single  $^{13}$ C at position 8 (red circle) is shown.




**Figure S2.** <sup>1</sup>H and <sup>13</sup>C spectra of roseobacticide A isolated from production cultures of *P. inhibens* DSM 17395 containing ring-<sup>2</sup>H<sub>4</sub>-L-tyrosine/pCA and 2-<sup>13</sup>C-L-tyrosine/pCA, respectively. (A, B) <sup>1</sup>H NMR spectrum of authentic roseobacticide A (A) and of roseobacticide A isolated from cultures containing ring-<sup>2</sup>H<sub>4</sub>-L-tyrosine (B). The arrows indicate a reduction in the integral of the phenol aromatic peaks consistent with <sup>2</sup>H incorporation. See also Table S1 for HR-ESI-MS data, which further corroborate this conclusion. The structure and numbering of ring-<sup>2</sup>H<sub>4</sub>-roseobacticide A isolated from cultures containing from cultures containing 2-<sup>13</sup>C-L-tyrosine (D). Incorporation of <sup>13</sup>C into the carbonyl C of roseobacticide A is observed. The structure and numbering of 2-<sup>13</sup>C-roseoabacticide A is shown. See Table S1 for HR-MS data.




**Figure S3.** <sup>1</sup>H NMR spectrum of roseobacticide B isolated from production cultures of *P. inhibens* DSM 17395 containing ring-<sup>2</sup>H<sub>5</sub>-L-phenylalanine and sinapic acid. <sup>1</sup>H NMR spectrum of authentic roseobacticide B (A) and of roseobacticide B isolated from cultures containing ring-<sup>2</sup>H<sub>5</sub>-L-phenylalanine/sinapic acid (B). The arrows indicate a reduction in the integral of the phenyl aromatic peaks and the protons at positions 4 and 5 consistent with <sup>2</sup>H incorporation. The structure of the <sup>2</sup>H<sub>7</sub>-roseobacticide B isolated B isolated S1 for HR-ESI-MS data.



**Figure S4.** NMR characterization of 13-F-roseobacticide A. (A, B) <sup>1</sup>H (A) and gCOSY (B) NMR spectra of pure 13-F-roseobacticide A generated by culturing *P. inhibens* DSM 17395 in the presence of 3-fluoro-DL-tyrosine and pCA. The inset in panel (A) shows an enlarged view of the downfield region of the <sup>1</sup>H NMR spectrum. The observed peaks are assigned and the structure and numbering of 13-F-roseobacticide A is shown. (C, D) <sup>19</sup>F NMR spectra of pure 13-F-roseobacticide A is shown. (C, D) <sup>19</sup>F NMR spectra of pure 13-F-roseobacticide A (C) and 3-fluoro-DL-tyrosine (D). Both spectra contain a single peak at –136 ppm. See Table S1 for HR-MS data.



**Figure S5.** <sup>1</sup>H and <sup>13</sup>C spectra of roseobacticide A isolated from production cultures of *P. inhibens* DSM 17395 containing ring-<sup>2</sup>H<sub>4</sub>-pCA or 2-<sup>13</sup>C-pCA, respectively. (A, B) <sup>1</sup>H NMR spectrum of authentic roseobacticide A (A) and of roseobacticide A isolated from cultures containing ring-<sup>2</sup>H<sub>4</sub>-pCA (B). The arrows indicate a reduction in the integral of the phenol aromatic peaks consistent with incorporation of <sup>2</sup>H at these positions. See also Table S1 for HR-ESI-MS data, which further corroborate this conclusion. The structure and numbering of <sup>2</sup>H<sub>4</sub>-roseobacticide A isolated from cultures containing 2-<sup>13</sup>C-pCA (D). Incorporation of <sup>13</sup>C into the carbonyl C of roseobacticide A is observed. The structure and numbering of 2-13C-roseobacticide A is shown. See Table S1 for HR-MS data.




**Figure S6.** HPLC-ESI-MS analysis of <sup>34</sup>S-roseobacticide B and <sup>34</sup>S<sub>2</sub>-roseobacticide E. (A) Analysis of *P. inhibens* DSM 17395 cultures grown in the presence of <sup>34</sup>S-Cys and sinapic acid. The peaks corresponding to roseobacticides B and E, as compared with standards, are marked. The UV-vis and mass spectra of these two peaks are displayed (B-E). The UV-vis spectra of roseobacticide B (B) and roseobacticide E (C) show the signature features typical for these two analogs. The mass spectrum of roseobacticide B (D) shows both <sup>32</sup>S- and <sup>34</sup>S-bearing isotopomers. See Table S1 for HR-MS data. The mass spectrum of roseobacticide E shows a mixture of <sup>32</sup>S-, <sup>34</sup>S, and <sup>34</sup>S<sub>2</sub>-bearing roseobacticide E isotopomers.

Experiment	Roseobacticide isotopomer/analog	[M+H] <sup>+</sup> <sub>calc</sub>	[M+H] <sup>+</sup> <sub>expt</sub>	∆ppm	Molecular Formula
1,2- <sup>13</sup> C <sub>2</sub> -phenylacetic acid, sinapic acid	В	270.0670	270.0673	1.1	C <sub>15</sub> ( <sup>13</sup> C)H <sub>13</sub> O <sub>2</sub> S
Ring- <sup>2</sup> H₅-phenylacetic acid, sinapic acid	В	271.0762	271.0745	2.5	$C_{16}H_{11}(^{2}H)_{2}O_{2}S$
Ring- <sup>2</sup> H <sub>5</sub> -indoleacetic acid	С	308.0745	308.0747	0.7	$C_{18}H_{14}NO_2S$
Ring- <sup>2</sup> H₅-∟-tryptophan, sinapic acid	С	313.1059	313.1063	1.3	$C_{18}H_9(^2H)_5NO_2S$
Ring- ${}^{2}H_{4}$ -L-tyrosine, pCA	А	289.0836	289.0838	0.7	$C_{16}H_9(^2H)_4O_3S$
2- <sup>13</sup> C-L-tyrosine, pCA	А	286.0619	286.0620	0.3	C <sub>15</sub> ( <sup>13</sup> C)H <sub>13</sub> O <sub>3</sub> S
Ring- <sup>2</sup> H₅-L- phenylalanine, sinapic acid	В	271.0762 274.0950 276.1076	271.0764 274.0953 276.1078	0.7 1.1 0.7	C <sub>16</sub> H <sub>11</sub> ( <sup>2</sup> H) <sub>2</sub> O <sub>2</sub> S C <sub>16</sub> H <sub>8</sub> ( <sup>2</sup> H) <sub>5</sub> O <sub>2</sub> S C <sub>16</sub> H <sub>6</sub> ( <sup>2</sup> H) <sub>7</sub> O <sub>2</sub> S
Ring- <sup>2</sup> H <sub>4</sub> -pCA	А	289.0836	289.0841	1.7	C <sub>16</sub> H <sub>9</sub> ( <sup>2</sup> H) <sub>4</sub> O <sub>3</sub> S
Ring- <sup>2</sup> H₄-pCA	D	321.0557	321.0557	0.0	$C_{16}H_9(^2H)_4O_3S_2$
2- <sup>13</sup> C-pCA	А	286.0619	286.0623	1.4	C <sub>15</sub> ( <sup>13</sup> C)H <sub>13</sub> O <sub>3</sub> S
3-F-DL-tyrosine, pCA	А	303.0491	303.0490	0.3	$C_{16}H_{12}FO_3S$
3-F-DL-tyrosine, pCA	D	335.0212	335.0207	1.5	$C_{16}H_{12}FO_3S_2$
Ring- <sup>2</sup> H <sub>5</sub> -phenylpyruvic acid, sinapic acid	В	274.0950	274.0954	1.5	$C_{16}H_8(^2H)_5O_2S$
Ring- <sup>2</sup> H₅-phenylglyoxylic acid, sinapic acid	В	269.0636	269.0638	0.7	$C_{16}H_{13}O_2S$
Ring- <sup>2</sup> H₅-phenylglycine, sinapic acid	В	269.0636	269.0639	1.1	$C_{16}H_{13}O_2S$
<sup>34</sup> S-L-Cysteine	В	271.0594	271.0592	0.7	C <sub>16</sub> H <sub>13</sub> O <sub>2</sub> ( <sup>34</sup> S)

 Table S1. HR-ESI-MS data for roseobacticide isotopomers and analogs.

## Table S2. NMR data for 13-F-roseobacticide A.



C/H	δ <sub>H</sub>	Integral, multiplicity (Hz)	$\delta_{\text{F}}$	COSY
4	8.68	1H, d (11.7)		H5
5	8.31	1H, dd (9.5, 11.7)		H4, H6
6	7.95	1H, dd (1.9, 9.5)		H5, H8 (weak)
7-SMe	2.55	3H, s		
8	8.22	1H, d (1.9)		H6 (weak)
12	8.71	1H, dd (2.1, 12.4)		F13, H16 (weak)
13		1F, s*	-136.4	H12, H15
15	8.38	1H, dd (8.5, 9.3)		H16, F13
16	8.68	1H, ddd (1.0, 2.1, 8.5)		H12, H15

\*<sup>19</sup>F NMR spectrum collected in <sup>1</sup>H-decoupled mode

## **Supporting Information References**

- 1- Brock, N. L.; Nikolay, A.; Dickschat, J. S. Chem. Commun. 2014, 50, 5487.
- 2- Robbins, R. J.; Schmidt, W. F. J. Label. Compd. Radiopharm. 2004, 47, 797.
- 3- Skowera, K.; Kanska, M. J. Label. Compd. Radiopharm. 2008, 51, 321.
- 4- Murata, S.; Sugiyama, K.; Tomioka, J. J. Org. Chem. 1993, 58, 1976.
- 5- Seyedsayamdost, M. R.; Carr, G.; Kolter, R.; Clardy, J. J. Am. Chem. Soc. 2011, 133, 18343.
- 6- Seyedsayamdost, M. R.; Case, R. J.; Kolter, R.; Clardy, J. Nat. Chem. 2011, 3, 331.
- 7- Buddruhs, N.; Pradella, S.; Göker, M.; Päuker, O.; Pukall, R.; Spröer, C.; Schumann, P.; Peterson, J.; Brinkhoff, T. *Int. J. Syst. Evol. Microbiol.* **2013**, *63*, 4340.

## *Complete citation for references (9) and (16) in the paper:*

(9) Holligan, P. M.; Fernandez, E.; Aiken, J.; Balch, W. M.; Boyd, P; Burkill, P. H.; Finch, M.; Groom, S. B.; Malin, G.; Muller, K.; Purdie, D. A.; Robinson, C.; Trees, C. C.; Turner, S. M.; van der Wal, P. *Global Biogeochem. Cycles* **1993**, *7*, 879.

(16) Wagner-Döbler, I.; Ballhausen, B.; Berger, M.; Brinkhoff, T.; Buchholz, I.; Bunk, B.; Cypionka, H.; Daniel, R.; Drepper, T.; Gerdts, G.; Hahnke, S.; Han, C.; Jahn, D.; Kalhoefer, D.; Kiss, H.; Klenk, H. P.; Kyrpides, N.; Liebl, W.; Liesegang, H.; Meincke, L.; Pati, A.; Petersen, J.; Piekarski, T.; Pommerenke, C.; Pradella, S.; Pukall, R.; Rabus, R.; Stackebrandt, E.; Thole, S.; Thompson, L.; Tielen, P.; Tomasch, J.; von Jan, M.; Wanphrut, N.; Wichels, A.; Zech, H.; Simon, M. *ISME J.* **2010**, *4*, 61.